Headquartered in Gaithersburg, Maryland, Novavax is a biotech company that develops vaccines and vaccine technologies, pairing protein-based nanoparticles with its proprietary Matrix-M® adjuvant. Its platform underpins marketed vaccines for COVID-19 and malaria, while the company continues in-house R&D and works with pharmaceutical, research and government partners to advance additional medicines. Novavax also conducts R&D and Matrix-M manufacturing in Uppsala, Sweden.
Comprehensive Compliance Program under California Health & Safety Code §119400-119402
Compliance program
Equal Employment Opportunity and Affirmative Action Compliance
Compliance program
TechnoVax IncFounded in 2004, privately held TechnoVax is a New York metro-area biotechnology company developing viral vaccines through a cell-based virus-like particle platform. Its near-clinical-stage work centers on vaccine candidates for influenza and RSV, including an inhaled powder approach developed with a pulmonary drug-delivery partner. The company also provides biological products and collaborative research services for vaccine, diagnostic, and research applications.ELMSFORD, NY
Sanaria IncRockville-based Sanaria develops whole-parasite sporozoite vaccines designed to protect people against malaria, with a particular focus on Plasmodium falciparum. Its custom Clinical Manufacturing Facility is described as the only facility of its type in the world, producing regulated, cryopreserved vaccine materials and research reagents. Founded by physician-scientist Stephen L. Hoffman, the company also coordinates a global PfSPZ research consortium involving more than 85 institutions.ROCKVILLE, MD
EVAX IncEVAX Inc. is the manufacturing and commercialization subsidiary of Enepret Incorporated, a company founded in 2017 to commercialize triterpene-production technologies developed at the University of Kentucky. Its lean team brings together synthetic-biology researchers and pharmaceutical manufacturing specialists to help vaccine developers move from early research into clinical work with non-animal adjuvants and their key ingredients. EVAX manufactures these materials in a 3,500-square-foot facility at the West Virginia University Innovation Corporation in Morgantown.MORGANTOWN, WV
POP Biotechnologies, IncBuffalo-based POP Biotechnologies develops nanotechnology platforms for vaccines, immunotherapies and light-activated cancer drug delivery. Its patented SNAP technology forms nanoliposome vaccines by binding His-tagged antigens to CoPoP liposomes, and has supported EuCorVac-19, a COVID-19 vaccine that met primary endpoints in a Phase 3 study. The company also produces CoPoP under GMP at a 2.5-million-dose scale and is advancing PhotoDOX, which uses red light to trigger localized doxorubicin release in solid tumors.BUFFALO, NY